These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37506979)

  • 1. Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
    Saraf A; Tahir I; Hu B; Dietrich AW; Tonnesen PE; Sharp GC; Tillman G; Roeland EJ; Nipp RD; Comander A; Peppercorn J; Fintelmann FJ; Jimenez RB
    Int J Radiat Oncol Biol Phys; 2024 Jan; 118(1):94-103. PubMed ID: 37506979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Full Compliance of Adjuvant Endocrine Therapy Is Associated with Higher Disease-Free Survival in Hormone Receptor-Positive and HER2-Negative Chinese Breast Cancer Patients with First Tumor Recurrence.
    Li Z; Liu Y; Li Y; Shang Y; Du K; Ji X; Han H; Zhang J
    Asian Pac J Cancer Prev; 2022 Oct; 23(10):3413-3420. PubMed ID: 36308366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
    Farias AJ; Du XL
    Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
    [No Abstract]   [Full Text] [Related]  

  • 4. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
    Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
    BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
    Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
    Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of adjuvant endocrine therapy in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy].
    Xia G; Zhu J; Yuan J; Cao B; Tang J; Chen Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(6):614-619. PubMed ID: 28247605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.
    Daly B; Olopade OI; Hou N; Yao K; Winchester DJ; Huo D
    JAMA Oncol; 2017 Jul; 3(7):928-935. PubMed ID: 28152150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
    Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
    JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
    Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
    Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
    Meneveau MO; Keim-Malpass J; Camacho TF; Anderson RT; Showalter SL
    Breast Cancer Res Treat; 2020 Dec; 184(3):805-816. PubMed ID: 32920742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery.
    Murphy CT; Li T; Wang LS; Obeid EI; Bleicher RJ; Eastwick G; Johnson ME; Hayes SB; Weiss SE; Anderson PR
    Clin Breast Cancer; 2015 Oct; 15(5):381-9. PubMed ID: 25861716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant therapy use among Appalachian breast cancer survivors.
    Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
    Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics and prognosis of patients with ipsilateral breast tumor recurrence after breast conservation therapy].
    Sun GY; Wang SL; Tang Y; Jin J; Song YW; Liu YP; Wang WH; Fang H; Chen SY; Ren H; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):352-358. PubMed ID: 29860762
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
    Vicini FA; Cecchini RS; White JR; Arthur DW; Julian TB; Rabinovitch RA; Kuske RR; Ganz PA; Parda DS; Scheier MF; Winter KA; Paik S; Kuerer HM; Vallow LA; Pierce LJ; Mamounas EP; McCormick B; Costantino JP; Bear HD; Germain I; Gustafson G; Grossheim L; Petersen IA; Hudes RS; Curran WJ; Bryant JL; Wolmark N
    Lancet; 2019 Dec; 394(10215):2155-2164. PubMed ID: 31813636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
    Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; Liefers GJ; Nortier JWR; Rutgers EJT; Seynaeve CM; van de Velde CJH;
    Eur J Cancer; 2018 May; 95():59-67. PubMed ID: 29635145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of trust in the acceptance of adjuvant endocrine therapy in breast cancer patients.
    Constanze E; Uwe G; Christoph T; Kavitha D; Dominik R; Urte S; Walter B
    Psychooncology; 2022 Dec; 31(12):2122-2131. PubMed ID: 36251608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving local control with breast-conserving therapy: a 27-year single-institution experience.
    Cabioglu N; Hunt KK; Buchholz TA; Mirza N; Singletary SE; Kuerer HM; Babiera GV; Ames FC; Sahin AA; Meric-Bernstam F
    Cancer; 2005 Jul; 104(1):20-9. PubMed ID: 15912514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
    Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
    J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer.
    Lee KT; Jacobs L; Walsh EM; Stearns V; Segal JB
    Breast Cancer Res Treat; 2020 Dec; 184(3):965-975. PubMed ID: 32914353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.